INOVIO PHARMACEUTICALS INC's ticker is INO and the CUSIP is 45773H201. A total of 231 filers reported holding INOVIO PHARMACEUTICALS INC in Q4 2020. The put-call ratio across all filers is 1.28 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2021 | $156,000 | +4.0% | 16,887 | 0.0% | 0.00% | – |
| Q4 2020 | $150,000 | -23.5% | 16,887 | 0.0% | 0.00% | – |
| Q3 2020 | $196,000 | -78.1% | 16,887 | -49.2% | 0.00% | -100.0% |
| Q2 2020 | $896,000 | +140.9% | 33,237 | -33.5% | 0.00% | 0.0% |
| Q1 2020 | $372,000 | +100.0% | 49,986 | -11.4% | 0.00% | – |
| Q4 2019 | $186,000 | +60.3% | 56,386 | 0.0% | 0.00% | – |
| Q3 2019 | $116,000 | -30.1% | 56,386 | +0.1% | 0.00% | – |
| Q2 2019 | $166,000 | +74.7% | 56,336 | +120.1% | 0.00% | – |
| Q1 2019 | $95,000 | -6.9% | 25,600 | 0.0% | 0.00% | – |
| Q4 2018 | $102,000 | -25.0% | 25,600 | -26.3% | 0.00% | – |
| Q2 2018 | $136,000 | -15.5% | 34,718 | +1.8% | 0.00% | – |
| Q1 2018 | $161,000 | +14.2% | 34,118 | 0.0% | 0.00% | – |
| Q4 2017 | $141,000 | +22.6% | 34,118 | +87.8% | 0.00% | – |
| Q3 2017 | $115,000 | – | 18,168 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| CAXTON ASSOCIATES LP | 784,679 | $643,437 | 0.10% |
| Green Alpha Advisors, LLC | 146,300 | $119,966 | 0.08% |
| Virtus ETF Advisers LLC | 54,106 | $44,367 | 0.02% |
| Cedar Brook Financial Partners, LLC | 104,881 | $86,002 | 0.02% |
| PROFUND ADVISORS LLC | 418,749 | $343,374 | 0.02% |
| Arlington Capital Management, Inc. | 27,735 | $22,743 | 0.02% |
| Hennion & Walsh Asset Management, Inc. | 382,158 | $313 | 0.02% |
| Rafferty Asset Management, LLC | 2,647,927 | $2,171,300 | 0.02% |
| Brainard Capital Management LLC | 16,666 | $13,666 | 0.01% |
| Beck Bode, LLC | 41,218 | $33,799 | 0.01% |